A Gated Community for Oncology Nurses and
Cancer Care Teams | More Info
Breast   |   Prostate   |   Lung   |   Hematology   |   Skin   |   Gastrointestinal   |   Genitourinary   |   Head / Neck   |   Brain   |   Gynecological   |   Sarcoma   |   Thyroid
Career  |  Exercise  |  Nutrition  |  Recipes  |  Survivorship  |  Symptom Management  |  Emergencies  |  Side Effects  |  Pediatrics  |  Complementary Therapies

About Us

TheONC is a community for oncology nurses and other healthcare professionals who collaborate as part of cancer care teams. The goal of this site is to support and connect oncology nurses and cancer team members to encourage knowledge sharing and optimize cancer care.

Most oncology sites act primarily as unidirectional, top-down resources. Nurses visit them to gather news, research, or advice. TheONC is different: It’s a safe place to share ideas, stories, and experiences.

TheONC participants are carefully vetted by the editorial curators of the site. Prior to submitting content participants must disclose conflicts of interest and be checked against the Office of the Inspector General of the Department of Health and Human Services to ensure that no contributing member has committed Medicare fraud in the past. Additionally, all comments are vetted by the editorial team to ensure relevance and appropriateness.

This is meant to be a true community for facilitating conversation and idea-sharing: Together we'll build a well of shared clinical knowledge and experience – one that can be tapped into quickly and easily to help oncology nurses solve the unique problems we face every day.

We welcome your feedback and comments. Contact:

Guest users may not comment or otherwise engage on the site. However, we encourage user contributions from oncology nurses and cancer care teams. This is primarily a site for and by nurses, and registration is required – that's one of the ways we can ensure TheONC stays true to its goal.

Editors review all posted comments before they go live. We're not looking to censor any opinions, just to ensure the quality of the content. We review them as quickly as possible, the moment they get submitted, during normal business hours. But if there is a slight delay, we appreciate your understanding. It's all in the name of keeping this space safe for oncology nurses and true to its mission.

Users, please make sure to review our Terms of Service and our Editorial Policy Statement. Here are few key points:

  • Don't post anything you don't have the right to post.
  • Don't post information that identifies individual patients, such as images of their faces, their names, or other details that would make it easy to name them.
  • Don't libel or inflame others.
  • Don't post product pitches.

You might also want to review The American Nurses Association's Social Networking Principles Toolkit and Principles for Social Networking and the Nurse.

TheONC is supported by an unrestricted grant from Bristol-Myers Squibb.

Webinar Series
Tuesday, October 29, 2013 12:00 PM EDT

Presented by Ellen T. Matloff, MS, CGC , this webinar will highlight:

  • How to determine which patients require genetic counseling
  • How to help prepare your patients for the genetic counseling process
  • Testing options that are now available
  • How you can utilize this data in managing your patients and their family members

Participants will also be able to ask questions during a live question and answer period with speaker Ellen T. Matloff, MS, CGC .

Wednesday, August 28, 2013 12:00 PM EDT
Wednesday, June 26, 2013 12:00 PM EDT
Wednesday, April 10, 2013 12:00 PM EDT
Have a question or topic but don't want to write a blog? Post it on our readerboards and get feedback from the community!
Patriotacp on Enhance your Business through Excellent Website Promotion
Patriotacp on Enhance your Business through Excellent Website Promotion
Patriotacp on Enhance your Business through Excellent Website Promotion
FDA Approves Onivyde for Advanced Pancreatic Cancer
Marijke Vroomen Durning, RN,
10/27/2015  3
On October 22, 2015, the US Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection, Merrimack Pharmaceuticals, Inc.), in combination with fluorouracil ...
Like Us on Facebook
on Twitter
TheONC Twitter Feed